Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy

Sudhalkar Eye Hospital (Other)
Overall Status
Completed ID

Study Details

Study Description

Brief Summary

Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known to reduce neovascularization and fibrovascular proliferation in inflammatory conditions, including post-operative inflammation. It has shown efficacy in numerous ocular conditions(off-label), that includes Age related macular degeneration, proliferative diabetic retinopathy, neovascular glaucoma and corneal neovascularization. It is being explored as an option for preventing recurrence of pterygium and as an adjunct to improving outcomes of trabeculectomy. There is a debate as to the mode and duration of bevacizumab administration for trabeculectomy. This study aims to compare a single subconjunctival dose of bevacizumab with topical therapy over one month in terms of outcomes of trabeculectomy surgery, non-progression of field loss and stable intraocular pressure(IOP) control.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Phacoemulsification

Study Design

Study Type:
Actual Enrollment :
180 participants
Intervention Model:
Parallel Assignment
Double (Participant, Investigator)
Primary Purpose:
Official Title:
Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma
Study Start Date :
Dec 1, 2007
Actual Primary Completion Date :
May 1, 2011
Actual Study Completion Date :
Jun 1, 2011

Arms and Interventions

Arm Intervention/Treatment
Experimental: Topical/Subconjunctival

Depending upon the mode of administration

Procedure: Phacoemulsification
Surgery for complications of trabeculectomy

Outcome Measures

Primary Outcome Measures

  1. Intraocular pressure control [For 2 years]

Secondary Outcome Measures

  1. Progression [2 years]

Eligibility Criteria


Ages Eligible for Study:
42 Years and Older
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • Primary Open Angle Glaucoma

  • Progression

  • Failure to reach target IOP

  • Non compliant

Exclusion Criteria:
  • Resurgery

  • Systemic contraindication to bevacizumab

  • All other forms of glaucoma

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Sudhalkar Eye Hospital


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Aditya Sudhalkar, Dr. Aditya Anand Sudhalkar, Sudhalkar Eye Hospital Identifier:
Other Study ID Numbers:
  • 31234EH
First Posted:
Aug 29, 2011
Last Update Posted:
Aug 29, 2011
Last Verified:
Aug 1, 2011
Keywords provided by Aditya Sudhalkar, Dr. Aditya Anand Sudhalkar, Sudhalkar Eye Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 29, 2011